Japan

Taiho Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Taiho Submits NDA for NK1 Receptor Antagonist Fosnetupitant for Prevention of Gastrointestinal Symptoms Associated with Cancer Chemotherapy

Lead Product(s): Fosnetupitant Chloride

Therapeutic Area: Gastroenterology Product Name: Pro-NETU

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 23, 2021

Details:

Taiho Pharmaceutical has submitted to the Japanese Ministry of Health, Labour and Welfare a new drug application for an NK1 receptor antagonist antiemetic drug for gastrointestinal symptoms (nausea and vomiting) associated with cancer chemotherapy.

Takeda Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

New Drug Application for Oral Disintegrated Tablet Formulation of TAKECAB® for Treatment of Acid-Related Disease

Lead Product(s): Vonoprazan Fumarate

Therapeutic Area: Gastroenterology Product Name: Takecab

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 22, 2021

Details:

Takeda has applied for approval to manufacture and market TAKECAB® OD 10 mg and TAKECAB® OD 20 mg as additional formulations of TAKECAB® 10 mg and TAKECAB® 20 mg, developed by Takeda for treating acid-related disease.